SEC Info - Revance Therapeutics, Inc.

SEC Info℠

Home

My Interests

Help

Please Sign In

Revance Therapeutics, Inc.
TN
SEC # 1479290

Click to view...

Registrant

About

Filings

Files

Relationships

Names

Topics

Web

*As Of*	*Filing*	*Page*	*Title*	*Docs.*

3/5/24	424B5	1	About This Prospectus	3
		1	About This Prospectus Supplement	2
3/21/24	DEF 14A	1	Annual Board and Committee Self Evaluations	1
		1	Annual Performance-Based Bonuses	1
		1	Board Cybersecurity Expertise	1
		1	Board Matters	1
		1	Board Matters-Information Regarding Committees of the Board	1
		1	Board Matters-Role of the Board in Risk Oversight	1
2/28/24	10-K	1	Business	1
3/21/24	DEF 14A	1	Ceo Pay Ratio	1
2/28/24	10-K	1	Certain Relationships and Related Transactions, and Director Independence	1
		1	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	1
3/21/24	DEF 14A	1	Company Performance Highlights	1
		1	Compensation	1
		1	Compensation Discussion & Analysis -- Annual Performance-Based Bonuses	1
		1	Compensation Discussion and Analysis	1
		1	Compensation Discussion and Analysis-Other Features of our Executive Compensation Program-Agreements with our NEOs	1
		1	Compensation Highlights	1
11/8/23	10-Q	1	Condensed Consolidated Balance Sheets	3
		1	Condensed Consolidated Financial Statements (Unaudited)	3
		1	Condensed Consolidated Statements of Cash Flows	3
		1	Condensed Consolidated Statements of Operations and Comprehensive Loss	3
		1	Condensed Consolidated Statements of Stockholders' Equity (Deficit)	3
2/28/24	10-K	1	Consolidated Balance Sheets	1
		1	Consolidated Statements of Cash Flows	1
		1	Consolidated Statements of Operations and Comprehensive Loss	1
		1	Consolidated Statements of Stockholders' Equity	1
3/21/24	DEF 14A	1	Contents	1
2/28/24	10-K	1	Controls and Procedures	4
3/21/24	DEF 14A	1	Corporate Governance	1
2/28/24	10-K	1	DAXXIFY for	1
11/8/23	10-Q	1	Defaults Upon Senior Securities	3
2/28/24	10-K	1	Defined Terms	4
3/21/24	DEF 14A	1	DELINQUENT SECTION 16(a) REPORTS	1
3/5/24	424B5	1	Description of Capital Stock	3
		1	Description of Debt Securities	3
		1	Description of Warrants	3
		1	Dilution	3
3/21/24	DEF 14A	1	Directors	1
2/28/24	10-K	1	Directors, Executive Officers and Corporate Governance	1
		1	Disclosure Regarding Foreign Jurisdictions That Prevent Inspections	1
3/5/24	424B5	1	Dividend Policy	2
3/21/24	DEF 14A	1	Equity Compensation Plan Information	1
		1	Esg	1
		1	Executive	1
		1	Executive Compensation	2
		1	Executive Compensation Program	1
		1	Executive Compensation Tables	1
		1	Executive Compensation Tables-Summary Compensation Table	1
		1	Executive Compensation-Compensation Discussion and Analysis	1
		1	Executive Compensation-Compensation Discussion and Analysis-Executive Compensation Policies and Practices-Results of 2023 Say-on-Pay Vote, Stockholder Outreach and Response	1
		1	Executive Compensation-Compensation Discussion and Analysis-Other Features of our Executive Compensation Program-Agreements with our NEOs-Stock Ownership Guidelines	1
		1	Executive Officers	1
11/8/23	10-Q	1	Exhibits	3
2/28/24	10-K	1	Exhibits and Financial Statement Schedules	1
3/5/24	424B5	1	Experts	3
2/28/24	10-K	1	F-11	1
		1	F-2	1
		1	F-5	1
		1	F-6	1
		1	F-7	1
		1	F-9	1
		1	F2-F4	1
3/21/24	DEF 14A	1	Factors Used in Determining Executive Compensation	1
2/28/24	10-K	1	Financial Statements and Supplementary Data	1
		1	Form 10-K Summary	1
3/21/24	DEF 14A	1	Ging Policy	1
		1	Grants of Plan-Based Awards for Fiscal Year 2023	1
		1	Householding of Proxy Materials	1
		1	How We Determine Executive Compensation-Factors Used in Determining Executive Compensation	1
3/5/24	424B5	1	Incorporation of Certain Information by Reference	3
3/21/24	DEF 14A	1	Insider Trading and Hed	1
		1	Legal Matters	4
3/5/24	424B5	1	Legal Ownership of Securities	3
2/28/24	10-K	1	Legal Proceedings	4
11/8/23	10-Q	1	Liquidity and Capital	1
2/28/24	10-K	1	Liquidity and Capital Resources	2
		1	Management's Discussion and Analysis of Financial Condition and Results of Operations	4
3/5/24	424B5	1	Market and Industry Data	2
2/28/24	10-K	1	Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	1
3/5/24	424B5	1	Material U.S. Federal Income Tax Consequences to Non-U.S. Holders of Our Common Stock	2
2/28/24	10-K	1	Mine Safety Disclosures	4
3/21/24	DEF 14A	1	Non-Employee Director Compensation	1
2/28/24	10-K	1	Note	1
11/8/23	10-Q	1	Note 1	3
2/28/24	10-K	1	Note 10	1
8/8/23	10-Q	1	Note 11	2
11/8/23	10-Q	1	Note 12	3
		1	Note 13	1
2/28/24	10-K	1	Note 15	1
		1	Note 16	1
		1	Note 2	4
		1	Note 3	2
		1	Note 4	3
11/8/23	10-Q	1	Note 5	1
2/28/24	10-K	1	Note 6	2
8/8/23	10-Q	1	Note 8	2
2/28/24	10-K	1	Note 9	2
11/8/23	10-Q	1	Notes to Condensed Consolidated Financial Statements	3
2/28/24	10-K	1	Notes to Consolidated Financial Statements	1
11/14/23	S-3ASR	1	Offering, The	1
3/21/24	DEF 14A	1	Option Exercises and Stock Vested in 2023	1
		1	Other Features of our Executive Compensation Program	1
2/28/24	10-K	1	Other Information	4
3/21/24	DEF 14A	1	Other Matters	1
2/28/24	10-K	1	Our Product	1
3/21/24	DEF 14A	1	Outstanding Equity Awards at Fiscal Year-End 2023	1
2/28/24	10-K	1	Part 1	1
		1	Part 1. Item 1A. Risk Factors	1
		1	Part I	4
		1	Part I. Item 1A. Risk Factors- Risks Related to Our Intellectual Property	1
		1	Part Ii	4
		1	Part Iii	1
		1	Part Iv	1
3/21/24	DEF 14A	1	Pay Versus Performance	1
3/5/24	424B5	1	Plan of Distribution	3
3/21/24	DEF 14A	1	Potential Payments upon Termination or Change in Control	1
		1	Potential Payments Upon Termination or Change in Control-Sjuts Separation Agreement	1
2/28/24	10-K	1	Power of Attorney (contained in the signature page to this Annual Report on Form 10-K)	1
11/14/23	S-3ASR	1	Power of Attorney (see signature pages)	1
2/28/24	S-8	1	Power of Attorney reference is made to the signature page of this Registration Statement	1
2/28/24	10-K	1	Principal Accountant Fees and Services	1
		1	Product Competition	1
		1	Properties	1
3/21/24	DEF 14A	1	Proposal 1	1
		1	Proposal 2	1
		1	Proposal 3	1
3/5/24	424B5	1	Prospectus Summary	3
		1	Prospectus Supplement Summary	2
3/21/24	DEF 14A	1	Proxy Card	1
		1	Proxy Summar	1
		1	Proxy Summary	1
2/28/24	10-K	1	Quantitative and Qualitative Disclosures about Market Risk	4
3/21/24	DEF 14A	1	Questions and Answers	1
		1	Questions and Answers About These Proxy Materials and Voting	1
2/28/24	10-K	1	Report of Independent Registered Public Accounting Firm	1
		1	Reserved	1
11/8/23	10-Q	1	Resources	1
3/5/24	424B5	1	Risk Factors	7
2/28/24	10-K	1	Risk Factors-Risks Related to our Intellectual Property	1
		1	Risks Related to Government and Industry Regulation	1
		1	Risks Related to Our Business and Strategy	1
3/21/24	DEF 14A	1	Role of the Board in Risk Oversight	1
		1	Security Ownership of Certain Beneficial Owners and Management	1
2/28/24	10-K	1	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	1
3/21/24	DEF 14A	1	Separation and Consulting Agreement with Mr. Sjuts	1
		1	Severance and Change in Control Benefits	1
2/28/24	10-K	1	Signatures	4
3/5/24	424B5	1	Special Note Regarding Forward-Looking Statements	4
3/21/24	DEF 14A	1	Stockholder Engagement	1
		1	Summary Compensation Table	1
		1	Summary Compensation Table for Fiscal Years 2023, 2022 and 2021	1
		1	Table of	1
3/5/24	424B5	1	Table of Contents	7
11/14/23	S-3ASR	1	The Offering	1
2/28/24	10-K	1	Therapeutic Indications	1
3/21/24	DEF 14A	1	Tockholder Engagement	1
		1	Transactions With Related Persons	1
3/5/24	424B5	1	Underwriting	2
11/8/23	10-Q	1	Unregistered Sales of Equity Securities and Use of Proceeds	3
2/28/24	10-K	1	Unresolved Staff Comments	1
3/21/24	DEF 14A	1	Use of Competitive Market Compensation Data	1
3/5/24	424B5	1	Use of Proceeds	3
2/28/24	10-K	1	Vii	1
3/5/24	424B5	1	Where You Can Find More Information	3
2/28/24	10-K	1	Ybersecurity	1

↑Top

Revance Therapeutics, Inc. TN SEC # 1479290

278 Topics within the Past Year Past Two Years Past Three Years Past Four Years Past Five Years Entire Database

Revance Therapeutics, Inc.
TN
SEC # 1479290

278 Topics
within the